Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06439654
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-03
First Post:
2024-05-28
Brief Title:
Atlantic Lipid Lowering Treatment Optimization Program
Sponsor:
Atlantic Health System
Organization:
Atlantic Health System
Study Overview
Official Title:
Atlantic Lipid Lowering Treatment Optimization Program ALLTOP A Comprehensive Approach to the Treatment of Familial Hypercholesterolemia and Complex Dyslipidemias
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ALLTOP
Brief Summary:
Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality To help address this in our community Atlantic Medical Group AMG formed a lipid workgroup chaired by Robert D Fishberg MD and Jeffrey N Feldman MD The overarching goal of the lipid workgroup is to enhance the treatment of lipid disorders in those patients with abnormal lipid levels by improving access to resources at the primary care practice level and specialty level We aim to develop a model for primary and secondary prevention that integrates guidelines for treatment at the practice level Our primary objective is to identify high-risk patients by utilizing the electronic health record and partnering with patients primary care providers to provide comprehensive medical management
Detailed Description:
This study will screen patients with LDL-C 160 mgdL and with evidence of familial hypertension reach out using secure chat to the attending practitioner of such patients and inform the practitioner of our comprehensive services to address FH A study team member will inform the practitioner that one of the study team plans to reach out to their patient to inform the patient of the study Unless one of the study team receives notification by the practitioner that they want to opt out of this service for their patients and do not want further interaction the patient will be informed of the study and the consent process
The research question is Will an innovative comprehensive outreach approach in conjunction with the primary care provider reduce LDL-C levels in individuals with familial hypercholesteremia below individual baseline values ideally at a level at or below 100 mgdL
The research question is Will an innovative comprehensive outreach approach in conjunction with the primary care provider reduce LDL-C levels in individuals with familial hypercholesteremia below individual baseline values ideally at a level at or below 100 mgdL
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None